Related Experiment Video
Updated: Sep 5, 2025
12:41
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
5.0K
Mini kidney organoids deliver maximal drug screening impact
Eryn E Dixon1, Shayna T J Bradford1, Benjamin D Humphreys2
1Division of Nephrology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Cell Stem Cell
|July 8, 2022
Summary
Researchers created a kidney organoid platform to test treatments for autosomal-dominant polycystic kidney disease (ADPKD). This system identified a promising new drug that effectively inhibits cyst growth in disease models.
Area of Science:
- Nephrology
- Stem Cell Biology
- Drug Discovery
Background:
- Autosomal-dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by cyst formation in the kidneys.
- Current treatments for ADPKD are limited, highlighting the need for novel therapeutic strategies.
- Kidney organoids offer a promising model for studying kidney development and disease.
Purpose of the Study:
- To develop a high-throughput platform for generating kidney organoids.
- To utilize this platform for identifying novel therapeutic targets and drug candidates for ADPKD.
- To evaluate the efficacy of identified compounds in inhibiting cyst growth in kidney organoid models.
Main Methods:
- Development of a novel platform for differentiating thousands of miniature kidney organoids.
- Each organoid contains one to two nephron-like structures.
- Utilizing the organoid platform to screen for inhibitors of cyst growth in ADPKD models.
Main Results:
- Successful development of a scalable kidney organoid differentiation platform.
- Identification of a potent inhibitor of cyst growth.
- Demonstration of the inhibitor's efficacy in organoid models of ADPKD.
Conclusions:
- The developed organoid platform enables efficient drug screening for kidney diseases.
- A novel inhibitor shows significant potential for treating autosomal-dominant polycystic kidney disease.
- This platform accelerates the discovery of new therapies for genetic kidney disorders.
